PHVS

Pharvaris

PHVS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,235

Bullish sentiment (50-day avg)61%

Price to earnings ratio-10.7

Market capitalization2.2B

Earnings per share-2.98

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-175.7M

Social

What share of all stock conversation is about PHVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 8

Pharvaris N.V. ($PHVS) announces positive topline data from the CHAPTER-3 pivotal study of Deucrictibant XR for prophylaxis of HAE attacks, with an 83% attack rate reduction versus placebo.
The stock rose 4.72% in 15 minutes after the news, with some analysts predicting a 40% share price move and a possible buyout.
Pharvaris has a cash runway to 2028, but some investors question whether it makes sense to raise capital given the recent results, while others predict the stock will increase by 50% or more.

Generated by AI

Sentiment

Of the messages about PHVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	80% new	62.86% +25.36	65.97% +12.05
Bearish	—	20% -80	37.14% -25.36	34.03% -12.05

Bullish· Sep 8

Pharvaris N.V. ($PHVS) has announced positive topline data from its Phase 3 trial, with a 27% surge in stock price.
The company's Phase 3 trial results showed an 83% reduction in HAE attack rate vs. placebo, with clean safety profiles and an expected NDA/MAA submission in 1H 2027.
Analysts and investors are bullish on Pharvaris, with one specialist fund predicting a 40% share price move and another expecting a commercial execution/m&A buyout play with a target price of $3.5-4.5B.

Bearish· Dec 12

The stock has broken below support levels, which could indicate a potential selloff.
The short interest in Pharvaris N.V. is high, with some traders already having taken positions shorting the stock.
The stock's price action is weak, with a recent spike failing to hold above $10, and a lack of volume supporting the price.

Generated by AI

Topics

Of the messages about PHVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	32.47%	67.62%
Analysts	—	100%	42.21%	14.07%
Technical Analysis	—	0%	0%	12.41%
Macro	—	0%	25.32%	5.9%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%

Announcements· Dec 6

Pharvaris N.V. (PHVS) has priced a $300 million underwritten offering of ordinary shares and pre-funded warrants to advance treatment for hereditary angioedema.
Pharvaris has announced positive top-line Phase 2 data from the CHAPTER-1 study of deucrictibant for the prophylactic treatment of hereditary angioedema.
Pharvaris has completed an 11.125 million share secondary priced at $24.00, with Morgan Stanley and Leerink acting as joint book running managers for the offering.

Technical Analysis· Dec 9

$PHVS RSI is super low and oversold, indicating a potential reversal.
The stock has formed a strong support line at $8.4, and the author is confident it will overcome short selling forces and go up.
The author has identified a potential buy opportunity at $8.77, with a key level at $9.60, and is expecting a bigger move after a 10.50 break.

Generated by AI

Community

Of the messages about PHVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	10%	56.23%	58.86%
Newcomers	—	90%	43.77%	41.14%

Regulars· Dec 6

Pharvaris N.V. shares have been trading at elevated volumes, with a 28.21% increase in value.
The company's deucrictibant has shown positive top-line phase 2 data in the CHAPTER-1 study, exceeding expectations and potentially positioning it favorably in the hereditary angioedema treatment market.
Pharvaris shares have spiked 33% after the company announced that its investigational drug met its primary goal in a clinical trial for the treatment and prevention of hereditary angioedema attacks.

Newcomers· Sep 8

The newcomers are focused on the positive topline data from the CHAPTER-3 pivotal study of Deucrictibant XR, which showed a significant reduction in hereditary angioedema attack rates.
The new investors are optimistic about Pharvaris' prospects, with some expecting a 40% share price move and others anticipating a higher price due to the company's strong results and potential for a write-up.
The newcomers are also discussing the potential for Pharvaris to raise capital again, despite the company's cash runway extending to 2028, and are questioning whether the recent capital increase would impact the stock price.

Generated by AI

Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary and secondary endpoints with statistical significance, supporting deucrictibant XR as a potential prophylactic treatment option. Management plans to use CHAPTER-3 data in upcoming marketing authorization applications for deucrictibant XR in hereditary angioedema. The statistically significant CHAPTER-3 outcome...

10d agoYahoo Finance

Pharvaris at H.C. Wainwright conference: dual HAE push gains pace

13d agoInvesting.com

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

14d agoYahoo Finance

Pharvaris at Morgan Stanley conference: oral HAE drug nears launch

14d agoInvesting.com

Cantor Fitzgerald reiterates Pharvaris stock rating after trial data

15d agoInvesting.com

Weekly Note: Two Approvals, Two Verdicts: Pharvaris' Oral Breakthrough Vs. Scholar Rock's Population Problem

16d agoSeeking Alpha

Also Discussed

Investors talking about PHVS also mention

#	Name	Attention
1	AMAM - Ambrx Biopharma Inc.	——
2	Oric Pharmaceuticals, Inc.ORIC	0%0
3	Belite Bio, Inc. ADRBLTE	0%new
4	ICVX - Icosavax, Inc.	——
5	Pyxis Oncology, Inc. Common StockPYXS	0%0
6	HARP - Harpoon Therapeutics, Inc.	——
7	Pharming Group N.V. ADRPHAR	0%+0
8	Phathom Pharmaceuticals, Inc.PHAT	0%new
9	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
10	OMIC - Singular Genomics Systems, Inc.	——

Pharvaris N.V. Ordinary Shares

Healthcare
Biotechnology

Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases. The company’s core work centers on bradykinin B2 receptor antagonists designed to address hereditary angioedema and related angioedema conditions through on-demand and preventive treatment options. Its current pipeline includes formulations intended for acute attack management as well as longer-acting prophylactic use, reflecting a portfolio built around differentiated oral approaches in a market still served by injectable and other traditional therapies. Pharvaris operates as a research-driven drug developer with activities spanning clinical development, regulatory engagement, and eventual commercialization of therapies for underserved patient populations. The company is headquartered in Zug, Switzerland.

Website

Location

Grafenauweg 8

Zug, 6300

Switzerland

Social

What share of all stock conversation is about PHVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 8

Pharvaris N.V. ($PHVS) announces positive topline data from the CHAPTER-3 pivotal study of Deucrictibant XR for prophylaxis of HAE attacks, with an 83% attack rate reduction versus placebo.
The stock rose 4.72% in 15 minutes after the news, with some analysts predicting a 40% share price move and a possible buyout.
Pharvaris has a cash runway to 2028, but some investors question whether it makes sense to raise capital given the recent results, while others predict the stock will increase by 50% or more.

Generated by AI

Sentiment

Of the messages about PHVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	80% new	62.86% +25.36	65.97% +12.05
Bearish	—	20% -80	37.14% -25.36	34.03% -12.05

Bullish· Sep 8

Pharvaris N.V. ($PHVS) has announced positive topline data from its Phase 3 trial, with a 27% surge in stock price.
The company's Phase 3 trial results showed an 83% reduction in HAE attack rate vs. placebo, with clean safety profiles and an expected NDA/MAA submission in 1H 2027.
Analysts and investors are bullish on Pharvaris, with one specialist fund predicting a 40% share price move and another expecting a commercial execution/m&A buyout play with a target price of $3.5-4.5B.

Bearish· Dec 12

The stock has broken below support levels, which could indicate a potential selloff.
The short interest in Pharvaris N.V. is high, with some traders already having taken positions shorting the stock.
The stock's price action is weak, with a recent spike failing to hold above $10, and a lack of volume supporting the price.

Generated by AI

Topics

Of the messages about PHVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	32.47%	67.62%
Analysts	—	100%	42.21%	14.07%
Technical Analysis	—	0%	0%	12.41%
Macro	—	0%	25.32%	5.9%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%

Announcements· Dec 6

Pharvaris N.V. (PHVS) has priced a $300 million underwritten offering of ordinary shares and pre-funded warrants to advance treatment for hereditary angioedema.
Pharvaris has announced positive top-line Phase 2 data from the CHAPTER-1 study of deucrictibant for the prophylactic treatment of hereditary angioedema.
Pharvaris has completed an 11.125 million share secondary priced at $24.00, with Morgan Stanley and Leerink acting as joint book running managers for the offering.

Technical Analysis· Dec 9

$PHVS RSI is super low and oversold, indicating a potential reversal.
The stock has formed a strong support line at $8.4, and the author is confident it will overcome short selling forces and go up.
The author has identified a potential buy opportunity at $8.77, with a key level at $9.60, and is expecting a bigger move after a 10.50 break.

Generated by AI

Community

Of the messages about PHVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	10%	56.23%	58.86%
Newcomers	—	90%	43.77%	41.14%

Regulars· Dec 6

Pharvaris N.V. shares have been trading at elevated volumes, with a 28.21% increase in value.
The company's deucrictibant has shown positive top-line phase 2 data in the CHAPTER-1 study, exceeding expectations and potentially positioning it favorably in the hereditary angioedema treatment market.
Pharvaris shares have spiked 33% after the company announced that its investigational drug met its primary goal in a clinical trial for the treatment and prevention of hereditary angioedema attacks.

Newcomers· Sep 8

The newcomers are focused on the positive topline data from the CHAPTER-3 pivotal study of Deucrictibant XR, which showed a significant reduction in hereditary angioedema attack rates.
The new investors are optimistic about Pharvaris' prospects, with some expecting a 40% share price move and others anticipating a higher price due to the company's strong results and potential for a write-up.
The newcomers are also discussing the potential for Pharvaris to raise capital again, despite the company's cash runway extending to 2028, and are questioning whether the recent capital increase would impact the stock price.

Generated by AI

Pharvaris

Social

Sep 8

Bullish· Sep 8

Bearish· Dec 12

Announcements· Dec 6

Technical Analysis· Dec 9

Regulars· Dec 6

Newcomers· Sep 8

What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?

Pharvaris at H.C. Wainwright conference: dual HAE push gains pace

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris at Morgan Stanley conference: oral HAE drug nears launch

Cantor Fitzgerald reiterates Pharvaris stock rating after trial data

Weekly Note: Two Approvals, Two Verdicts: Pharvaris' Oral Breakthrough Vs. Scholar Rock's Population Problem

Also Discussed

Pharvaris N.V. Ordinary Shares

Company Information

Location

What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?

Pharvaris at H.C. Wainwright conference: dual HAE push gains pace

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris at Morgan Stanley conference: oral HAE drug nears launch

Cantor Fitzgerald reiterates Pharvaris stock rating after trial data

Weekly Note: Two Approvals, Two Verdicts: Pharvaris' Oral Breakthrough Vs. Scholar Rock's Population Problem

Also Discussed

Social

Sep 8

Bullish· Sep 8

Bearish· Dec 12

Announcements· Dec 6

Technical Analysis· Dec 9

Regulars· Dec 6

Newcomers· Sep 8